BCAL diagnostics
Breast cancer blood screening. For every woman, everywhere.

19 October 2026

RESULTS OF ANNUAL GENERAL MEETING

BCAL Diagnostics Limited (ASX: BDX) ("BCAL" or "Company) is pleased to advise that at the Annual General Meeting (AGM) held on 19 October 2026, all resolutions put to Shareholder were passed on a poll.

In accordance with Listing Rule 3.13.2 and Corporations Act Section 251AA(2) the voting results and proxies received and poll results are as set out in the attached report.

The Chair voted all Discretionary Votes in favour of the Resolutions.

This announcement was approved by the Company Secretary.

Guy Robertson
Company Secretary

For further information contact:

Jayne Shaw
Chair
Jshaw@bcaldiagnostics.com

Anne-Louise Arnett
Chief Executive Officer
aarnett@bcaldiagnostics.com

BCAL Diagnostics Limited

Appendix

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2

Table 1 BCAL Diagnostics 2026 Annual General Meeting Results

Resolution details		Instructions given to validly appointed proxies (as at proxy close)					Number of votes cast on the poll (where applicable)				Resolution Result
Resolution	**Resolution Type**	**For**	**Against**	**Proxy'sDiscretion**	**Exclusions**	**Abstain**	**For**	**Against**	**Exclusions**	**Abstain**	**Carried / Not Carried**
1. Adoption of Remuneration Report	Ordinary	79,627,223	17,200	36,000	62,704,462	28,437,205	79,663,223	17,200	62,704,462	28,437,205	Carried
		99.93%	0.02%	0.05%			99.98%	0.02%			
2. Re-election of Director – Ms Jayne Shaw	Ordinary	142,344,885		36,000		28,441,205	142,380,885	0	0	28,441,205	Carried
		99.97%	0.00%	0.03%			100.00%	0.00%			
3. Re-Election of Director Mark McConnell	Ordinary	112,310,810		36,000		58,475,280	112,346,810	0		58,475,280	Carried
		99.97%	0.00%	0.03%			100.00%	0.00%			
4. Approval of the Issue of 1,400,000 Convertible Notes under the Convertible Note facility and up to 14,513,838 Shares to be issued on conversion.	Ordinary	84,436,970	17,200	36,000	57,894,715	28,437,205	84,472,970	17,200	57,894,715	28,437,205	Carried
		99.94%	0.02%	0.04%			99.98%	0.02%			
5. Approval of the Issue of 1,000,000 Convertible Notes under the Convertible Note facility and up to 10,367,098 Shares to be issued on conversion to a related party.	Ordinary	109,661,298	17,200	36,000	32,670,387	28,437,205	109,697,298	17,200	32,670,387	28,437,205	Carried
		99.95%	0.02%	0.03%			99.98%	0.02%			
6. Ratification of Convertible Notes drawn under the Convertible Note Facility.	Ordinary	84,436,970	17,200	36,000	57,894,715	28,437,205	84,472,970	17,200	57,894,715	28,437,205	Carried
		99.94%	0.02%	0.04%			99.98%	0.02%			
7. Approval of additional 10% Placement Capacity	Special	142,331,685	17,200	36,000		28,437,205	142,367,685	17,200		28,437,205	Carried
		99.96%	0.01%	0.03%			99.99%	0.01%			